Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today announced that it will present two late-breaking posters at the American Association for Cancer Research (AACR) Annual Meeting taking place April 8-13, 2022 in New Orleans, LA.
| CAMBRIDGE, Mass., March 9, 2022 /PRNewswire/ -- Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today announced that it will present two late-breaking posters at the American Association for Cancer Research (AACR) Annual Meeting taking place April 8-13, 2022 in New Orleans, LA.
Details of the Myeloid posters are below: Title: ATAK receptors, a new class of chimeric antigen receptors that harness innate immunity in myeloid cells to target cancer Title: In vivo programming of myeloid cells by mRNA mediated delivery of novel Fc alpha fusion receptor activates anti-tumor immunity Abstracts and full session details can be accessed through the AACR meeting planner: AACR Annual Meeting 2022 | April 8-13, 2022 | New Orleans About Myeloid Therapeutics Myeloid Media Contact Investor Contact
SOURCE Myeloid Therapeutics, Inc. |
View original content to download multimedia:
